查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2049230

抗憂鬱症市場：依藥物類別、疾病類型、藥物類型、通路和地區分類，2026-2034 年

Depression Drugs Market Report by Drug Class, Disorder Type, Drug Type, Distribution Channel, and Region 2026-2034
出版日期: | 出版商: IMARC | 英文 140 Pages | 商品交期: 2-3個工作天內

價格

2025年全球抗憂鬱症市場規模達197億美元。展望未來，IMARC Group預測，到2034年，該市場規模將達到254億美元，2026年至2034年的複合年成長率為2.79%。推動市場成長的因素包括：久坐不動的生活方式和壓力導致憂鬱症患者人數不斷增加；藥物製劑和給藥技術的進步；以及人們對行動應用程式和線上治療平台等數位治療方法的興趣日益濃厚。

憂鬱症是一種精神障礙，其特徵是缺乏正向情緒、持續低落的情緒以及許多認知、生理、行為和情緒症狀。診斷主要依據症狀和患者的病歷。治療方法是使用抗憂鬱症，這類藥物透過調節大腦中神經傳導物質（如血清素）的活性來控制患者的情緒。這些藥物也有助於緩解焦慮症狀、季節性情感障礙和持續性憂鬱症。

根據世界衛生組織（世衛組織）的數據，憂鬱症是精神障礙的主要原因之一，影響全球超過2.64億人。社交焦慮症和憂鬱症精神疾病的日益普遍是推動抗憂鬱症市場成長的主要因素之一。此外，世界各國政府實施的全國性封鎖和嚴格的社交距離措施改變了相當一部分人的日常生活，對個人心理健康產生了負面影響。這一趨勢正成為推動抗憂鬱症銷售成長要素。此外，旨在開發副作用最小、療效更持久的抗憂鬱症的新技術不斷湧現，以及人們對新藥接受度的提高，預計將在未來幾年推動市場成長。

這份最新報告深入剖析了全球抗憂鬱症市場的各個關鍵面向。報告涵蓋了從宏觀市場概覽到微觀層面的產業表現、近期趨勢、主要市場促進因素和挑戰、SWOT分析、波特五力分析以及價值鏈分析等各方面。對於行業相關人員、投資者、研究人員、顧問、商務策略以及所有對抗憂鬱症市場的人士而言，這份報告都是必讀之作。

本報告解答的主要問題

  • 全球抗憂鬱症市場規模有多大？
  • 新冠疫情對全球抗憂鬱症市場產生了哪些影響？
  • 全球抗憂鬱症市場的預期成長率是多少？
  • 推動全球抗憂鬱症市場發展的主要因素是什麼？
  • 全球抗憂鬱症市場按疾病類型分類的組成是什麼？
  • 全球抗憂鬱症市場按分銷管道分類的組成是怎樣的？
  • 全球抗憂鬱症市場的主要區域有哪些？
  • 全球抗憂鬱症市場的主要公司和參與者有哪些？

目錄

第1章：序言

第2章：調查方法

  • 調查目的
  • 相關利益者
  • 數據來源
    • 主要訊息
    • 次要訊息
  • 市場估值
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章執行摘要

第4章：引言

第5章：全球抗憂鬱症市場

  • 市場概覽
  • 市場表現
  • 新冠疫情的影響
  • 市場區隔：依藥物類別分類
  • 市場區隔：依疾病類型
  • 市場區隔：依藥物類型
  • 市場區隔：依分銷通路分類
  • 市場區隔：按地區
  • 市場預測

第6章 市場區隔：依藥物類別分類

  • 非典型抗精神病藥物
  • 血清素-正腎上腺素再回收抑制劑（SNRIs）
  • 選擇性血清素再回收抑制劑（SSRIs）
  • 中樞神經系統（CNS）興奮劑
  • 三環抗憂鬱藥物
  • 單胺氧化酵素抑制劑
  • 其他

第7章 市場區隔：依疾病類型分類

  • 重度憂鬱症
  • 強迫症
  • 整體焦慮症
  • 恐慌症
  • 其他

第8章 市場區隔：依藥物類型分類

  • 學名藥
  • 品牌藥品

第9章 市場區隔：依分銷通路分類

  • 醫院藥房
  • 零售藥房
  • 網路藥房
  • 其他

第10章 市場區隔：依地區分類

  • 北美洲
  • 歐洲
  • 亞太地區
  • 中東和非洲
  • 拉丁美洲

第11章 SWOT 分析

第12章：價值鏈分析

第13章：波特五力分析

第14章：價格分析

第15章 競爭格局

  • 市場結構
  • 大公司
  • 主要公司簡介
    • Otsuka Pharmaceutical
    • Pfizer
    • Eli Lilly and Company
    • AstraZeneca
    • Novartis
    • Bristol-Myers Squibb
    • GlaxoSmithKline
    • Takeda Pharmaceutical Company
    • Allergan
    • Johnson & Johnson
    • Zhejiang NHU Company Ltd
    • Sebela Pharmaceuticals
Product Code: SR112026A1563

The global depression drugs market size reached USD 19.7 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 25.4 Billion by 2034, exhibiting a growth rate (CAGR) of 2.79% during 2026-2034. The growing cases of depression among the masses due to sedentary lifestyle and stress, increasing advancements in drug formulation and delivery techniques, and rising preferences for digital therapeutics, such as mobile apps and online therapy platforms, are some of the factors impelling the market growth.

Depression is a mental disorder characterized by the absence of positive emotions, constant low mood and numerous cognitive, physical, behavioral and emotional symptoms. It is diagnosed by identifying the symptoms and checking the medical history of the patient. It is then treated using depression drugs, which balance the functioning of neurotransmitters, such as serotonin, in the brain and controlling the mood and emotions of the patient. These drugs can assist in relieving the signs of anxiety, seasonal affective disorder and dysthymia.

According to the World Health Organization (WHO), depression is one of the leading causes of disability and has impacted more than 264 million people across the globe. The increasing prevalence of mental disorders, such as social anxiety and depression, represents one of the key factors propelling the depression drugs market growth. Moreover, as governments of various countries have imposed complete lockdown and are promoting the adoption of social distancing measures, the everyday routine of a significant portion of the population has been altered, which, in turn, has negatively impacted the mental health of individuals. This trend has emerged as another major growth-inducing factor boosting the sales of depression drugs. Furthermore, the emergence of novel techniques for the development of antidepressants with minimal side-effects and long-term results, in confluence with the increasing acceptance of new medications, is anticipated to impel the market growth in the upcoming years.

The latest report provides a deep insight into the global depression drugs market covering all its essential aspects. This ranges from macro overview of the market to micro details of the industry performance, recent trends, key market drivers and challenges, SWOT analysis, Porter's five forces analysis, value chain analysis, etc. This report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the depression drugs market in any manner.

Key Market Segmentation:

The publisher provides an analysis of the key trends in each segment of the market, along with forecasts at the global and regional levels for 2026-2034. Our report has categorized the market based on drug class, disorder type, drug type, and distribution channel.

Breakup by Drug Class:

  • Atypical Antipsychotics
  • Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
  • Selective Serotonin Reuptake Inhibitors (SSRIs)
  • Central Nervous System (CNS) Stimulants
  • Tricyclic Antidepressants
  • Monoamine Oxidase Inhibitors
  • Others

Breakup by Disorder Type:

  • Major Depressive Disorder
  • Obsessive-Compulsive Disorder
  • Generalized Anxiety Disorder
  • Panic Disorder
  • Others

Breakup by Drug Type:

  • Generic Drugs
  • Branded Drugs

Breakup by Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others

Breakup by Region:

  • North America
  • Europe
  • Asia Pacific
  • Middle East and Africa
  • Latin America

Competitive Landscape:

The report has also analyzed the competitive landscape of the market with some of the key players being Otsuka Pharmaceutical, Pfizer, Eli Lilly and Company, AstraZeneca, Novartis, Bristol-Myers Squibb, GlaxoSmithKline, Takeda Pharmaceutical Company, Allergan, Johnson & Johnson, Zhejiang NHU Company Ltd, Sebela Pharmaceuticals, etc.

Key Questions Answered in This Report

  • What is the size of the global depression drugs market?
  • What has been the impact of COVID-19 on the global depression drugs market?
  • What is the expected growth rate of the global depression drugs market?
  • What are the key factors driving the global depression drugs market?
  • What is the breakup of the global depression drugs market based on the disorder type?
  • What is the breakup of the global depression drugs market based on the distribution channel?
  • What are the key regions in the global depression drugs market?
  • Who are the key companies/players in the global depression drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Depression Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Breakup by Drug Class
  • 5.5 Market Breakup by Disorder Type
  • 5.6 Market Breakup by Drug Type
  • 5.7 Market Breakup by Distribution Channel
  • 5.8 Market Breakup by Region
  • 5.9 Market Forecast

6 Market Breakup by Drug Class

  • 6.1 Atypical Antipsychotics
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Selective Serotonin Reuptake Inhibitors (SSRIs)
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Central Nervous System (CNS) Stimulants
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Tricyclic Antidepressants
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Monoamine Oxidase Inhibitors
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast
  • 6.7 Others
    • 6.7.1 Market Trends
    • 6.7.2 Market Forecast

7 Market Breakup by Disorder Type

  • 7.1 Major Depressive Disorder
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Obsessive-Compulsive Disorder
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Generalized Anxiety Disorder
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Panic Disorder
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Others
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Market Breakup by Drug Type

  • 8.1 Generic Drugs
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Branded Drugs
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast

9 Market Breakup by Distribution Channel

  • 9.1 Hospital Pharmacies
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Retail Pharmacies
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Online Pharmacies
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast
  • 9.4 Others
    • 9.4.1 Market Trends
    • 9.4.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 Market Trends
    • 10.1.2 Market Forecast
  • 10.2 Europe
    • 10.2.1 Market Trends
    • 10.2.2 Market Forecast
  • 10.3 Asia Pacific
    • 10.3.1 Market Trends
    • 10.3.2 Market Forecast
  • 10.4 Middle East and Africa
    • 10.4.1 Market Trends
    • 10.4.2 Market Forecast
  • 10.5 Latin America
    • 10.5.1 Market Trends
    • 10.5.2 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porter's Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Otsuka Pharmaceutical
    • 15.3.2 Pfizer
    • 15.3.3 Eli Lilly and Company
    • 15.3.4 AstraZeneca
    • 15.3.5 Novartis
    • 15.3.6 Bristol-Myers Squibb
    • 15.3.7 GlaxoSmithKline
    • 15.3.8 Takeda Pharmaceutical Company
    • 15.3.9 Allergan
    • 15.3.10 Johnson & Johnson
    • 15.3.11 Zhejiang NHU Company Ltd
    • 15.3.12 Sebela Pharmaceuticals

List of Figures

  • Figure 1: Global: Depression Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Depression Drugs Market: Sales Value (in Billion USD), 2020-2025
  • Figure 3: Global: Depression Drugs Market: Breakup by Drug Class (in %), 2025
  • Figure 4: Global: Depression Drugs Market: Breakup by Disorder Type (in %), 2025
  • Figure 5: Global: Depression Drugs Market: Breakup by Drug Type (in %), 2025
  • Figure 6: Global: Depression Drugs Market: Breakup by Distribution Channel (in %), 2025
  • Figure 7: Global: Depression Drugs Market: Breakup by Region (in %), 2025
  • Figure 8: Global: Depression Drugs Market Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 9: Global: Depression Drugs Industry: SWOT Analysis
  • Figure 10: Global: Depression Drugs Industry: Value Chain Analysis
  • Figure 11: Global: Depression Drugs Industry: Porter's Five Forces Analysis
  • Figure 12: Global: Depression Drugs (Atypical Antipsychotics) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 13: Global: Depression Drugs (Atypical Antipsychotics) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 14: Global: Depression Drugs (Serotonin-Norepinephrine Reuptake Inhibitors) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 15: Global: Depression Drugs (Serotonin-Norepinephrine Reuptake Inhibitors) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 16: Global: Depression Drugs (Selective Serotonin Reuptake Inhibitors) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 17: Global: Depression Drugs (Selective Serotonin Reuptake Inhibitors) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 18: Global: Depression Drugs (Central Nervous System (CNS) Stimulants) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 19: Global: Depression Drugs (Central Nervous System (CNS) Stimulants) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 20: Global: Depression Drugs (Tricyclic Antidepressants) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 21: Global: Depression Drugs (Tricyclic Antidepressants) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 22: Global: Depression Drugs (Monoamine Oxidase Inhibitors) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 23: Global: Depression Drugs (Monoamine Oxidase Inhibitors) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 24: Global: Depression Drugs (Other Drug Classes) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 25: Global: Depression Drugs (Other Drug Classes) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 26: Global: Depression Drugs (Major Depressive Disorder) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 27: Global: Depression Drugs (Major Depressive Disorder) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 28: Global: Depression Drugs (Obsessive-Compulsive Disorder) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 29: Global: Depression Drugs (Obsessive-Compulsive Disorder) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 30: Global: Depression Drugs (Generalized Anxiety Disorder) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 31: Global: Depression Drugs (Generalized Anxiety Disorder) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 32: Global: Depression Drugs (Panic Disorder) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 33: Global: Depression Drugs (Panic Disorder) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 34: Global: Depression Drugs (Other Disorder Types) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 35: Global: Depression Drugs (Other Disorder Types) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 36: Global: Depression Drugs (Generic Drugs) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 37: Global: Depression Drugs (Generic Drugs) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 38: Global: Depression Drugs (Branded Drugs) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 39: Global: Depression Drugs (Branded Drugs) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 40: Global: Depression Drugs Market: Sales through Hospital Pharmacies (in Million USD), 2020 & 2025
  • Figure 41: Global: Depression Drugs Market Forecast: Sales through Hospital Pharmacies (in Million USD), 2026-2034
  • Figure 42: Global: Depression Drugs Market: Sales through Retail Pharmacies (in Million USD), 2020 & 2025
  • Figure 43: Global: Depression Drugs Market Forecast: Sales through Retail Pharmacies (in Million USD), 2026-2034
  • Figure 44: Global: Depression Drugs Market: Sales through Online Pharmacies (in Million USD), 2020 & 2025
  • Figure 45: Global: Depression Drugs Market Forecast: Sales through Online Pharmacies (in Million USD), 2026-2034
  • Figure 46: Global: Depression Drugs Market: Sales through Other Distribution Channels (in Million USD), 2020 & 2025
  • Figure 47: Global: Depression Drugs Market Forecast: Sales through Other Distribution Channels (in Million USD), 2026-2034
  • Figure 48: North America: Depression Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 49: North America: Depression Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 50: Europe: Depression Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 51: Europe: Depression Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 52: Asia Pacific: Depression Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 53: Asia Pacific: Depression Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 54: Middle East and Africa: Depression Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 55: Middle East and Africa: Depression Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 56: Latin America: Depression Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 57: Latin America: Depression Drugs Market Forecast: Sales Value (in Million USD), 2026-2034

List of Tables

  • Table 1: Global: Depression Drugs Market: Key Industry Highlights, 2025 and 2034
  • Table 2: Global: Depression Drugs Market Forecast: Breakup by Drug Class (in Million USD), 2026-2034
  • Table 3: Global: Depression Drugs Market Forecast: Breakup by Disorder Type (in Million USD), 2026-2034
  • Table 4: Global: Depression Drugs Market Forecast: Breakup by Drug Type (in Million USD), 2026-2034
  • Table 5: Global: Depression Drugs Market Forecast: Breakup by Distribution Channel (in Million USD), 2026-2034
  • Table 6: Global: Depression Drugs Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 7: Global: Depression Drugs Market Structure
  • Table 8: Global: Depression Drugs Market: Key Players